Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessMarketsDr Reddy’s Q1: Just an overdose of Revlimid, not much growth ahead, say brokerages

    Dr Reddy’s Q1: Just an overdose of Revlimid, not much growth ahead, say brokerages

    Even though the company’s profit, revenue and profitability exceeded expectations, brokerages feel that the growth in recent quarters was fueled by the spectacular sales of Revlimid. They say the contribution from the drug will soon start waning out, and many still retain their ‘hold’ and ‘sell’ calls.

    Vaibhavi Ranjan
    July 28, 2023 / 12:14 IST
    Dr Reddy's office building
    • PRO Panorama

      Moneycontrol Pro Panorama | IPO Paradox: Fundraising soars, returns shrink

      Nov 27, 2025 / 03:36 PM IST

      Moneycontrol Pro Panorama November 27 edition: IMF advises India to keep policy flexible until clarity on US tariff, the banking l...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts